No doubt some investors will see this as Stem cells failing in all treatments, and a SP to fall significantly.
For all we know MSB relied on funding from Novartis for ARDS, MSB pressured them to update their support of this , and Novartis decided to terminate, concentrate elsewhere. Who knows?
We all make judgements at times like these, but for me it is not an indicator of future failure relating to heart, back and GVHD treatments ; not yet anyway!
Ann: Update on Novartis Agreement, page-66
-
- There are more pages in this discussion • 785 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |